{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:02:56Z","timestamp":1785247376125,"version":"3.55.0"},"reference-count":189,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated remarkable efficacy in tumors carrying BRCA1\/2 pathogenic variants (PVs) through the mechanism of synthetic lethality. PVs in other homologous recombination (HR) genes may also impair homologous recombination repair and confer sensitivity to PARPis; however, their predictive value remains uncertain and appears to vary according to the affected gene and tumor type. We review and critically discuss the current evidence regarding the predictive value of non-BRCA HR gene pathogenic variants as biomarkers of PARPi sensitivity across ovarian, breast, prostate, and pancreatic cancers. A narrative review was conducted between October 2023 and December 2025, first identifying pivotal clinical trials of PARP inhibitors across ovarian, breast, prostate, and pancreatic cancers, followed by a targeted search of PubMed, Embase, Web of Science, and Google Scholar for relevant preclinical and clinical studies. Seventeen clinical studies and multiple preclinical reports were analyzed regarding genomic frequency, HRD association, and treatment response. Preclinical studies consistently demonstrated increased PARPi sensitivity in models with alterations in several non-BRCA HR genes. Clinical evidence, however, was heterogeneous. PALB2 demonstrated the strongest and most consistent association with PARPi benefit across tumor types, while RAD51C and RAD51D also showed clinically meaningful activity, particularly in ovarian cancer. In contrast, evidence supporting PARPi sensitivity in tumors harboring ATM, CHEK2, CDK12, and several other HR gene alterations remained limited or inconsistent. Differences in gene function, biallelic inactivation, variant type, and current limitations of HRD companion diagnostic assays likely contribute to the observed variability in clinical response. Non-BRCA HR gene alterations represent promising predictive biomarkers for PARPi therapy but should not be considered a homogeneous group. Future biomarker-driven studies integrating comprehensive genomic profiling and functional assessment of homologous recombination deficiency are needed to refine patient selection and optimize the clinical application of PARPis beyond BRCA1\/2-associated cancers.<\/jats:p>","DOI":"10.3390\/ijms27156754","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:07:33Z","timestamp":1785244053000},"page":"6754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-4668","authenticated-orcid":false,"given":"Elizabeth Santana","family":"dos Santos","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, A.C. Camargo Cancer Center, S\u00e3o Paulo 01509-010, Brazil"},{"name":"Department of Oncogenetics, Hospital S\u00edrio Liban\u00eas, S\u00e3o Paulo 01308-050, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-9925","authenticated-orcid":false,"given":"Andr\u00e9 Luiz","family":"Cicilini","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, A.C. Camargo Cancer Center, S\u00e3o Paulo 01509-010, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda Evangelista","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Hospital S\u00edrio Liban\u00eas, S\u00e3o Paulo 01308-050, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Baz","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Genetics Laboratory, Department of Medical Biology and Pathology, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-9388","authenticated-orcid":false,"given":"Sandrine M.","family":"Caputo","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institut Curie, Paris Sciences and Lettres (PSL) University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Genetics Laboratory, Department of Medical Biology and Pathology, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Romeo, M., Pardo, J.C., Mart\u00ednez-Card\u00fas, A., Mart\u00ednez-Balibrea, E., Quiroga, V., Mart\u00ednez-Rom\u00e1n, S., Sol\u00e9, F., Margel\u00ed, M., and Mes\u00eda, R. (2018). Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103249"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.gim.2021.08.016","article-title":"Risks of Breast and Ovarian Cancer for Women Harboring Pathogenic Missense Variants in BRCA1 and BRCA2 Compared with Those Harboring Protein Truncating Variants","volume":"24","author":"Li","year":"2022","journal-title":"Genet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2300091","DOI":"10.1200\/PO.23.00091","article-title":"Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients with Somatic BRCA1\/2, Germline PALB2, or Homologous Recombination Deficiency Signature","volume":"7","author":"Batalini","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_6","first-page":"179","article-title":"Use of Poly ADP-Ribose Polymerase [PARP] Inhibitors in Cancer Cells Bearing DDR Defects: The Rationale for Their Inclusion in the Clinic","volume":"35","author":"Cerrato","year":"2016","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bulcan.2017.09.007","article-title":"Abnormalities of DNA repair and gynecological cancers","volume":"104","author":"Auguste","year":"2017","journal-title":"Bull. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3892\/br.2017.990","article-title":"Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer","volume":"7","author":"Kawahara","year":"2017","journal-title":"Biomed. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-Cancer Analysis of Bi-Allelic Alterations in Homologous Recombination DNA Repair Genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","article-title":"BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis","volume":"112","author":"Kalachand","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with Veliparib or Placebo in Metastatic Triple-Negative Breast Cancer and BRCA Mutation-Associated Breast Cancer (S1416): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_12","first-page":"PO.17.00286","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100445","DOI":"10.1016\/j.modpat.2024.100445","article-title":"Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance","volume":"37","author":"Romey","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PAP.0000000000000177","article-title":"Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2","volume":"25","author":"Hoang","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41525-019-0087-6","article-title":"High Frequency of Pathogenic Germline Variants within Homologous Recombination Repair in Patients with Advanced Cancer","volume":"4","author":"Bertelsen","year":"2019","journal-title":"npj Genom. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.clinre.2022.101880","article-title":"BRCA1 and RAD51C Promotor Methylation in Human Resectable Pancreatic Adenocarcinoma","volume":"46","author":"Abdallah","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","article-title":"Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer","volume":"29","author":"Tang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/jmg-2023-109325","article-title":"Mosaic BRCA1 Promoter Methylation Contribution in Hereditary Breast\/Ovarian Cancer Pedigrees","volume":"61","author":"Schwartz","year":"2024","journal-title":"J. Med. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103620","DOI":"10.1016\/j.breast.2023.103620","article-title":"Male Breast Cancer: No Evidence for Mosaic BRCA1 Promoter Methylation Involvement","volume":"73","author":"Schwartz","year":"2024","journal-title":"Breast Edinb. Scotl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13148-025-01885-1","article-title":"High Prevalence of Constitutional BRCA1 Epimutation in Patients with Early-Onset Triple-Negative Breast Cancer","volume":"17","author":"Schwartz","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115534","DOI":"10.1016\/j.ejca.2025.115534","article-title":"Predictive Value of BRCA1\/RAD51C Methylation in HGSOC\u2014An Ancillary Study of the PAOLA-1\/ENGOT-Ov25 Phase 3 Trial","volume":"225","author":"Blons","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_24","first-page":"15","article-title":"Role of Biomarkers in the Development of PARP Inhibitors","volume":"8","author":"Ganguly","year":"2016","journal-title":"Biomark. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","article-title":"ShallowHRD: Detection of Homologous Recombination Deficiency from Shallow Whole Genome Sequencing","volume":"36","author":"Eeckhoutte","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-21-1673","article-title":"Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial","volume":"27","author":"Schouten","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41388-023-02839-8","article-title":"Shallow Whole Genome Sequencing Approach to Detect Homologous Recombination Deficiency in the PAOLA-1\/ENGOT-OV25 Phase-III Trial","volume":"42","author":"Callens","year":"2023","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2200555","DOI":"10.1200\/PO.22.00555","article-title":"Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma","volume":"7","author":"Christinat","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1158\/1078-0432.CCR-23-0898","article-title":"Validation of the Clinical Use of GIScar, an Academic-Developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer","volume":"29","author":"Leman","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2023.04.020","article-title":"PARP Inhibitor Predictive Value of the Leuven HRD Test Compared with Myriad MyChoice CDx PLUS HRD on 468 Ovarian Cancer Patients from the PAOLA-1\/ENGOT-Ov25 Trial","volume":"188","author":"Loverix","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Willing, E.-M., Vollbrecht, C., V\u00f6ssing, C., Weist, P., Schallenberg, S., Herbst, J.M., Schatz, S., J\u00f3ri, B., Bataillon, G., and Harter, P. (2023). Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers, 15.","DOI":"10.3390\/cancers15133445"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29442","DOI":"10.1038\/s41598-025-14122-9","article-title":"Preliminary Evaluation of ShallowHRD Performance Compared to HRDetect in Familial Breast Cancer Tumors","volume":"15","author":"Baekgaard","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_35","first-page":"e2200258","article-title":"Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1\/ENGOT-Ov25 Trial","volume":"7","author":"Brown","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Aguilar-Quesada, R., Mu\u00f1oz-G\u00e1mez, J.A., Mart\u00edn-Oliva, D., Peralta, A., Valenzuela, M.T., Mat\u00ednez-Romero, R., Quiles-P\u00e9rez, R., Menissier-de Murcia, J., de Murcia, G., and Ruiz de Almod\u00f3var, M. (2007). Interaction between ATM and PARP-1 in Response to DNA Damage and Sensitization of ATM Deficient Cells through PARP Inhibition. BMC Mol. Biol., 8.","DOI":"10.1186\/1471-2199-8-29"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A Synthetic Lethal siRNA Screen Identifying Genes Mediating Sensitivity to a PARP Inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"EMBO J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_40","first-page":"95","article-title":"ATM-Depletion in Breast Cancer Cells Confers Sensitivity to PARP Inhibition","volume":"32","author":"Prodosmo","year":"2013","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM Protein Expression and Depletion of P53 Correlates with Olaparib Sensitivity in Gastric Cancer Cell Lines","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1535-7163.MCT-15-1002","article-title":"ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis","volume":"15","author":"Subhash","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.dnarep.2008.08.014","article-title":"A High-Throughput RNA Interference Screen for DNA Repair Determinants of PARP Inhibitor Sensitivity","volume":"7","author":"Lord","year":"2008","journal-title":"DNA Repair"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR Inhibition Disrupts Rewired Homologous Recombination and Fork Protection Pathways in PARP Inhibitor-Resistant BRCA-Deficient Cancer Cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26273","DOI":"10.1038\/srep26273","article-title":"Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer","volume":"6","author":"Ozden","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/0008-5472.CAN-09-4716","article-title":"Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells","volume":"70","author":"Gottipati","year":"2010","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2016.08.246","article-title":"Inactivation of the Tumor Suppressor BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) Gene Confers Increased Susceptibility to Platinum Antineoplastic Agents and Augments the Synergistic Response to Poly (ADP-Ribose) Polymerase (PARP) Inhibition in Ovarian Epithelial Cells","volume":"143","author":"Ciccone","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-Wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1\/2 Inhibitor Sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","article-title":"Ovarian Cancer-Associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-Ribose) Polymerase Inhibitors","volume":"289","author":"Joshi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Duan, W., Gao, L., Aguila, B., Kalvala, A., Otterson, G.A., and Villalona-Calero, M.A. (2014). Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00368"},{"key":"ref_53","first-page":"e9172","article-title":"A RAD51 Assay Feasible in Routine Tumor Samples Calls PARP Inhibitor Response beyond BRCA Mutation","volume":"10","author":"Cruz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-10-1120","article-title":"MRE11 Deficiency Increases Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers","volume":"71","author":"Vilar","year":"2011","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4161\/cc.22026","article-title":"Evaluation of Candidate Biomarkers to Predict Cancer Cell Sensitivity or Resistance to PARP-1 Inhibitor Treatment","volume":"11","author":"Oplustilova","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Koppensteiner, R., Samartzis, E.P., Noske, A., von Teichman, A., Dedes, I., Gwerder, M., Imesch, P., Ikenberg, K., Moch, H., and Fink, D. (2014). Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer in Vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100041"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1158\/1078-0432.CCR-14-0176","article-title":"Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer","volume":"20","author":"Lajud","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nsmb.1915","article-title":"Cooperation of Breast Cancer Proteins PALB2 and Piccolo BRCA2 in Stimulating Homologous Recombination","volume":"17","author":"Buisson","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/cas.12281","article-title":"Involvement of Homologous Recombination in the Synergism between Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition","volume":"104","author":"Sakogawa","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib","volume":"12","author":"Min","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline Mutations in RAD51D Confer Susceptibility to Ovarian Cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive Molecular Profiling of Lung Adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: Somatic Cancer Genetics at High-Resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Jette, N.R., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M., Williams, G.J., Bose, P., and Lees-Miller, S.P. (2020). ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers, 12.","DOI":"10.3390\/cancers12030687"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","article-title":"Health Risks for Ataxia-Telangiectasia Mutated Heterozygotes: A Systematic Review, Meta-Analysis and Evidence-Based Guideline","volume":"90","author":"Roeleveld","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","article-title":"Risk of Pancreatic Cancer Among Individuals with Pathogenic Variants in the ATM Gene","volume":"7","author":"Hsu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10689-021-00248-y","article-title":"First International Workshop of the ATM and Cancer Risk Group (4\u20135 December 2019)","volume":"21","author":"Lesueur","year":"2022","journal-title":"Fam. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and Ovarian Cancer Penetrance Estimates Derived from Germline Multiple-Gene Sequencing Results in Women","volume":"1","author":"Kurian","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Muvaffak, A., and Coleman, K.G. (2024). PARP Inhibitor Synthetic Lethality in ATM Biallelic Mutant Cancer Cell Lines Is Associated with BRCA1\/2 and RAD51 Downregulation. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1380633"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors","volume":"9","author":"Williamson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 Trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/13543784.2017.1389895","article-title":"Directing the Use of DDR Kinase Inhibitors in Cancer Treatment","volume":"26","author":"Brandsma","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2217\/epi.15.82","article-title":"Emerging Roles of ATRX in Cancer","volume":"7","author":"Watson","year":"2015","journal-title":"Epigenomics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101147","DOI":"10.1016\/j.tranon.2021.101147","article-title":"Loss of ATRX Confers DNA Repair Defects and PARP Inhibitor Sensitivity","volume":"14","author":"Garbarino","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Alenezi, W.M., Fierheller, C.T., Recio, N., and Tonin, P.N. (2020). Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes, 11.","DOI":"10.3390\/genes11080856"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-Scale Meta-Analysis of Mutations Identified in Panels of Breast\/Ovarian Cancer-Related Genes\u2014Providing Evidence of Cancer Predisposition Genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., Gonz\u00e1lez-Neira, A., Luccarini, C., Wahlstr\u00f6m, C., Pooley, K.A., Parsons, M.T., and Fortuno, C. (2021). Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women. N. Engl. J. Med., 384, 428\u2013439.","DOI":"10.1056\/NEJMoa1913948"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Lesueur, F., Eon-Marchais, S., Bonnet-Boissinot, S., Beauvallet, J., Dondon, M.-G., Golmard, L., Rouleau, E., Garrec, C., Martinez, M., and Toulas, C. (2021). TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing. Cancers, 13.","DOI":"10.3390\/cancers13153659"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000452082","article-title":"Bloom\u2019s Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition","volume":"8","author":"Cunniff","year":"2017","journal-title":"Mol. Syndromol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2741\/e767","article-title":"BRIP1, a Potential Candidate Gene in Development of Non-BRCA1\/2 Breast Cancer","volume":"8","author":"Ouhtit","year":"2016","journal-title":"Front. Biosci. Elite Ed."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/1541-7786.MCR-17-0357","article-title":"Combining Homologous Recombination and Phosphopeptide-Binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk","volume":"17","author":"Petitalot","year":"2019","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ygyno.2020.09.040","article-title":"Inhibition of Poly(ADP-Ribose) Polymerase Induces Synthetic Lethality in BRIP1 Deficient Ovarian Epithelial Cells","volume":"159","author":"Ciccone","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., and Qian, A. (2020). CDK12: A Potent Target and Biomarker for Human Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9061483"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell Cycle, CDKs and Cancer: A Changing Paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The Cyclin K\/Cdk12 Complex Maintains Genomic Stability via Regulation of Expression of DNA Damage Response Genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1086\/375121","article-title":"The CHEK2 1100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer Phenotype","volume":"72","author":"Wijnen","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2005.05.5160","article-title":"Increased Risk of Breast Cancer Associated with CHEK2*1100delC","volume":"25","author":"Weischer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2017.05.045","article-title":"Colorectal Cancer Risk Associated with the CHEK2 1100delC Variant","volume":"83","author":"Katona","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of Individuals with Germline Pathogenic\/Likely Pathogenic Variants in CHEK2: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Fang, C.-B., Wu, H.-T., Zhang, M.-L., Liu, J., and Zhang, G.-J. (2020). Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00160"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15252\/embj.201693860","article-title":"Interplay between Fanconi Anemia and Homologous Recombination Pathways in Genome Integrity","volume":"35","author":"Michl","year":"2016","journal-title":"EMBO J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"AACR Project GENIE Consortium (2017). AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A Truncating Mutation of HDAC2 in Human Cancers Confers Resistance to Histone Deacetylase Inhibition","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Enhances Anti-Tumor Effects of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitor Olaparib in Triple-Negative Breast Cancer Cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel Dual Inhibitors of PARP and HDAC Induce Intratumoral STING-Mediated Antitumor Immunity in Triple-Negative Breast Cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-019-1100-5","article-title":"MRE11-RAD50-NBS1 Complex Alterations and DNA Damage Response: Implications for Cancer Treatment","volume":"18","author":"Bian","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","article-title":"Microsatellite Instability Induced Mutations in DNA Repair Genes CtIP and MRE11 Confer Hypersensitivity to Poly (ADP-Ribose) Polymerase Inhibitors in Myeloid Malignancies","volume":"98","author":"Gaymes","year":"2013","journal-title":"Haematologica"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.21853","article-title":"Germline Mutations 657del5 of the NBS1 Gene Contribute Significantly to the Incidence of Breast Cancer in Central Poland","volume":"119","author":"Steffen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Wu, S., Zhou, J., Zhang, K., Chen, H., Luo, M., Lu, Y., Sun, Y., and Chen, Y. (2020). Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00301"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"17334","DOI":"10.18632\/oncotarget.24671","article-title":"Full In-Frame Exon 3 Skipping of BRCA2 Confers High Risk of Breast and\/or Ovarian Cancer","volume":"9","author":"Caputo","year":"2018","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated with Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-019-0180-9","article-title":"PPP2R2A Prostate Cancer Haploinsufficiency Is Associated with Worse Prognosis and a High Vulnerability to B55\u03b1\/PP2A Reconstitution That Triggers Centrosome Destabilization","volume":"8","author":"Zhao","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cancergen.2011.05.002","article-title":"Evaluation of PPP2R2A as a Prostate Cancer Susceptibility Gene: A Comprehensive Germline and Somatic Study","volume":"204","author":"Cheng","year":"2011","journal-title":"Cancer Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/1535-7163.MCT-21-0880","article-title":"Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death","volume":"22","author":"Avelar","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/s41598-024-76801-3","article-title":"Characterization of RNF144B and PPP2R2A Identified by a Novel Approach Using TCGA Data in Ovarian Cancer","volume":"15","author":"Manasa","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN Tumor Suppression","volume":"133","author":"Salmena","year":"2008","journal-title":"Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.4161\/cc.8.14.8947","article-title":"Cell Cycle Checkpoint Defects Contribute to Genomic Instability in PTEN Deficient Cells Independent of DNA DSB Repair","volume":"8","author":"Gupta","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0046-8177(98)90389-6","article-title":"Clinical and Pathological Features of Breast Disease in Cowden\u2019s Syndrome: An Underrecognized Syndrome with an Increased Risk of Breast Cancer","volume":"29","author":"Schrager","year":"1998","journal-title":"Hum. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jmg.2011.088807","article-title":"Predicting PTEN Mutations: An Evaluation of Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome Clinical Features","volume":"48","author":"Pilarski","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2016.01.004","article-title":"Copy Number Deletion of RAD50 as Predictive Marker of BRCAness and PARP Inhibitor Response in BRCA Wild Type Ovarian Cancer","volume":"141","author":"Zhang","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canrad.2011.05.004","article-title":"Double strand break repair, one mechanism can hide another: Alternative non-homologous end joining","volume":"16","author":"Rass","year":"2012","journal-title":"Cancer Radioth\u00e9rapie J. Soci\u00e9t\u00e9 Fr. Radioth\u00e9rapie Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"(2020). Role of Rad51 and DNA Repair in Cancer: A Molecular Perspective. Pharmacol. Ther., 208, 107492.","DOI":"10.1016\/j.pharmthera.2020.107492"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1139\/bcb-2016-0012","article-title":"Novel Insights into RAD51 Activity and Regulation during Homologous Recombination and DNA Replication","volume":"94","author":"Godin","year":"2016","journal-title":"Biochem. Cell Biol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Sullivan, M.R., and Bernstein, K.A. (2018). RAD-Ical New Insights into RAD51 Regulation. Genes, 9.","DOI":"10.20944\/preprints201811.0541.v1"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41586-023-06179-1","article-title":"Structure and Function of the RAD51B-RAD51C-RAD51D-XRCC2 Tumour Suppressor","volume":"619","author":"Greenhough","year":"2023","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-023-06219-w","article-title":"Structural Insights into BCDX2 Complex Function in Homologous Recombination","volume":"619","author":"Rawal","year":"2023","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinre.2013.10.011","article-title":"XRCC3 Thr241Met Polymorphism and Gastric Cancer Susceptibility: A Meta-Analysis","volume":"38","author":"Qin","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and Breast Cancer Risks Associated with Pathogenic Variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Golmard, L., Caux-Moncoutier, V., Davy, G., Al Ageeli, E., Poirot, B., Tirapo, C., Michaux, D., Barbaroux, C., d\u2019Enghien, C.D., and Nicolas, A. (2013). Germline Mutation in the RAD51B Gene Confers Predisposition to Breast Cancer. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-484"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41431-017-0021-2","article-title":"Contribution of Germline Deleterious Variants in the RAD51 Paralogs to Breast and Ovarian Cancers","volume":"25","author":"Golmard","year":"2017","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41523-021-00339-0","article-title":"Germline RAD51B Variants Confer Susceptibility to Breast and Ovarian Cancers Deficient in Homologous Recombination","volume":"7","author":"Setton","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1007\/s11033-021-06434-6","article-title":"Association between RAD51, XRCC2 and XRCC3 Gene Polymorphisms and Risk of Ovarian Cancer: A Case Control and an in Silico Study","volume":"48","author":"Paul","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/MMBR.66.4.630-670.2002","article-title":"Role of RAD52 Epistasis Group Genes in Homologous Recombination and Double-Strand Break Repair","volume":"66","author":"Symington","year":"2002","journal-title":"Microbiol. Mol. Biol. Rev. MMBR"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"103421","DOI":"10.1016\/j.dnarep.2022.103421","article-title":"A Moving Target for Drug Discovery: Structure Activity Relationship and Many Genome (de)Stabilizing Functions of the RAD52 Protein","volume":"120","author":"Bhat","year":"2022","journal-title":"DNA Repair"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Rossi, M.J., DiDomenico, S.F., Patel, M., and Mazin, A.V. (2021). RAD52: Paradigm of Synthetic Lethality and New Developments. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.780293"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Balboni, B., Rinaldi, F., Previtali, V., Ciamarone, A., Girotto, S., and Cavalli, A. (2023). Novel Insights into RAD52\u2019s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies. Cancers, 15.","DOI":"10.3390\/cancers15061817"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10238-025-01781-1","article-title":"Targeting the Werner Syndrome Protein in Microsatellite Instability Cancers: Mechanisms and Therapeutic Potential","volume":"25","author":"Chen","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall Survival in Patients with Platinum-Sensitive Recurrent Serous Ovarian Cancer Receiving Olaparib Maintenance Monotherapy: An Updated Analysis from a Randomised, Placebo-Controlled, Double-Blind, Phase 2 Trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma after Response to Platinum Therapy (ARIEL3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the PAOLA-1\/ENGOT-Ov25 Trial","volume":"34","author":"Leary","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","article-title":"Olaparib Maintenance Monotherapy in Platinum-Sensitive Relapsed Ovarian Cancer Patients without a Germline BRCA1\/BRCA2 Mutation: OPINION Primary Analysis","volume":"164","author":"Poveda","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e35707","DOI":"10.1002\/cncr.35707","article-title":"Olaparib as Treatment for Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency: Phase 2 LIGHT Study Final Overall Survival Analysis","volume":"131","author":"Liu","year":"2025","journal-title":"Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A Phase II Study of Talazoparib Monotherapy in Patients with Wild-Type BRCA1 and BRCA2 with a Mutation in Other Homologous Recombination Genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients with Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-21-1789","article-title":"Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513","volume":"27","author":"Chiorean","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis from the Phase II TRITON2 Study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib Monotherapy in Metastatic Castration-Resistant Prostate Cancer with DNA Repair Alterations (TALAPRO-1): An Open-Label, Phase 2 Trial","volume":"22","author":"Mehra","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and DNA Repair Gene Defects (GALAHAD): A Multicentre, Open-Label, Phase 2 Trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"LBA16","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final Overall Survival (OS) in PROpel: Abiraterone (Abi) and Olaparib (Ola) versus Abiraterone and Placebo (Pbo) as First-Line (1L) Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2022.06.017","article-title":"Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Phase II LIGHT Study Primary Analysis","volume":"166","author":"Cadoo","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/JCO-25-02075","article-title":"TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients with Metastatic Breast Cancer with Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2","volume":"44","author":"Tung","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A Mutational Signature Reveals Alterations Underlying Deficient Homologous Recombination Repair in Breast Cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the Mutational Signature of Homologous Recombination Deficiency in Clinical Samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13059-019-1867-0","article-title":"Correlation of Homologous Recombination Deficiency Induced Mutational Signatures with Sensitivity to PARP Inhibitors and Cytotoxic Agents","volume":"20","author":"Rusz","year":"2019","journal-title":"Genome Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.32143","article-title":"Antitumor Efficacy of PARP Inhibitors in Homologous Recombination Deficient Carcinomas","volume":"145","author":"Yi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: Public Archive of Interpretations of Clinically Relevant Variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Cline, M.S., Liao, R.G., Parsons, M.T., Paten, B., Alquaddoomi, F., Antoniou, A., Baxter, S., Brody, L., Cook-Deegan, R., and Coffin, A. (2018). BRCA Challenge: BRCA Exchange as a Global Resource for Variants in BRCA1 and BRCA2. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007752"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/humu.23818","article-title":"Large Scale Multifactorial Likelihood Quantitative Analysis of BRCA1 and BRCA2 Variants: An ENIGMA Resource to Support Clinical Variant Classification","volume":"40","author":"Parsons","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-Based Recommendations for Gene-Specific ACMG\/AMP Variant Classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ajhg.2021.09.003","article-title":"Classification of 101 BRCA1 and BRCA2 Variants of Uncertain Significance by Cosegregation Study: A Powerful Approach","volume":"108","author":"Caputo","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/ito.2024.419","article-title":"Consortium FrOG. FrOG\u2014The French OncoGenetics database","volume":"10","author":"Castera","year":"2024","journal-title":"Innov. Th\u00e9rapeutiques Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10549-012-2009-5","article-title":"Rare Germline Large Rearrangements in the BRCA1\/2 Genes and Eight Candidate Genes in 472 Patients with Breast Cancer Predisposition","volume":"133","author":"Rouleau","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Ben Aissa-Haj, J., Pinheiro, H., Cornelis, F., Sebai, M., Meseure, D., Briaux, A., Berteaux, P., Lefol, C., Des Guetz, G., and Trassard, M. (2022). The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1\/2 Negative and Breast Cancer Susceptibility. Genes, 13.","DOI":"10.3390\/genes13122213"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-021-00361-2","article-title":"Value of the Loss of Heterozygosity to BRCA1 Variant Classification","volume":"8","author":"Spurdle","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Aucouturier, C., Soirat, N., Cast\u00e9ra, L., Bertrand, D., Atkinson, A., Lavol\u00e9, T., Goardon, N., Quesnelle, C., Levilly, J., and Barbachou, S. (2024). Fine Mapping of RNA Isoform Diversity Using an Innovative Targeted Long-Read RNA Sequencing Protocol with Novel Dedicated Bioinformatics Pipeline. BMC Genom., 25.","DOI":"10.1186\/s12864-024-10741-0"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41525-025-00522-3","article-title":"A Founder BRCA1 Exonic Duplication Involving Breakpoint in T2T Reference Genome-Specific Region Results in Constitutional Fusion Transcript","volume":"10","author":"Schwartz","year":"2025","journal-title":"npj Genom. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-026-00906-3","article-title":"Constitutional BRCA1 Methylation Is Associated with High Level of Tumoral BRCA1 Methylation and Homologous Recombination Deficiency in Triple-Negative Breast Cancer","volume":"12","author":"Pasanisi","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ajhg.2026.05.015","article-title":"Homologous Recombination Deficiency-Driven Genomic Instability in Ovarian Cancer as an Indicator of BRCA1 and BRCA2 Variant Pathogenicity","volume":"113","author":"Schnaiter","year":"2026","journal-title":"Am. J. Hum. Genet."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in the Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of Resistance to Therapies Targeting BRCA-Mutant Cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Dilmac, S., and Ozpolat, B. (2023). Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Cancers, 15.","DOI":"10.3390\/cancers15143642"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Zhao, Q., Bai, L., Tan, Y., and Qie, M. (2024). Limitations of Homologous Recombination Status Testing and Poly (ADP-Ribose) Polymerase Inhibitor Treatment in the Current Management of Ovarian Cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1435029"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1021\/acschembio.5c00111","article-title":"Exploring the Potential of Homologous Recombination Protein PALB2 in Synthetic Lethal Combinations","volume":"20","author":"Lu","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2025.43.4_suppl.727","article-title":"Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated (HRD) Metastatic Pancreatic Cancer","volume":"43","author":"Jazieh","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Bitar, J.S., Mita, M., McAndrew, P., Park, D., Basho, R., Di Padova, J., Lauzon, M., and Yuan, Y. (2025). Abstract P3-10-19: Phase II Trial of Pembrolizumab in Combination with Olaparib in Advanced Breast Cancer with BRCA-Mutation or Homologous Recombination Defect (HRD). Clin. Cancer Res., 31.","DOI":"10.1158\/1557-3265.SABCS24-P3-10-19"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1535-7163.MCT-24-0515","article-title":"Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency","volume":"24","author":"Simoneau","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Olivucci, G., Iovino, E., Innella, G., Turchetti, D., Pippucci, T., and Magini, P. (2024). Long Read Sequencing on Its Way to the Routine Diagnostics of Genetic Diseases. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1374860"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2022.11.007","article-title":"Association and Performance of Polygenic Risk Scores for Breast Cancer among French Women Presenting or Not a Familial Predisposition to the Disease","volume":"179","author":"Jiao","year":"2023","journal-title":"Eur. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:09:22Z","timestamp":1785244162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":189,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156754"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156754","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}